Literature DB >> 8989255

A combined test using desmopressin and corticotropin-releasing hormone in the differential diagnosis of Cushing's syndrome.

J Newell-Price1, L Perry, S Medbak, J Monson, M Savage, M Besser, A Grossman.   

Abstract

To assess the ability of desmopressin to differentiate between pituitary and ectopic ACTH-dependent Cushing's syndrome and to determine whether diagnostic accuracy could be improved by administering it together with human sequence CRH, we examined its effects on cortisol and ACTH secretion when given alone or in combination with CRH in patients with Cushing's syndrome of varied etiology and compared these data to the results of a standard CRH test in the same individuals. Each patient was studied on three occasions, in random order, separated by at least 48 h. At 0900 h, via an indwelling forearm cannula, 10 micrograms desmopressin, 100 micrograms CRH, or a combination of the two were given as an iv bolus; thereafter, blood was drawn every 15 min for 2 h. The responses to the individual agents were determined according to the timing and calculation criteria suggested by Nieman et al. (1993). A total of 25 patients with Cushing's syndrome were studied: 17 patients with pituitary-dependent Cushing's syndrome, Cushing's disease (CD); 5 patients with occult ectopic ACTH secretion (EC); and 3 patients with primary adrenal (ACTH-independent) Cushing's syndrome. In this series, the best discrimination among ACTH-dependent patient groups was achieved using the combined test. Using the responses of plasma cortisol, all 17 patients with CD showed a rise greater than any of the 5 patients with EC, whereas 1 patient with CD showed a plasma ACTH response within the range seen in the patients with EC. Plasma cortisol responses to desmopressin alone were seen in 14 of 17 patients with CD and 1 of 5 patients with EC and, after CRH alone, in 15 of 17 patients with CD but in no patient with EC. In contrast, plasma ACTH responses after CRH alone were seen in 14 of 17 patients with CD and 2 of 5 patients with EC and, after desmopressin alone, in 12 of 17 with CD and 3 of 5 with EC, thus indicating overlapping responses between the groups and poorer discrimination. No responses were seen in the ACTH-independent group. These data indicate that desmopressin causes the secretion of ACTH and cortisol in patients with ACTH-dependent Cushing's syndrome, and that in combination with CRH, it may provide an improvement over the standard CRH test in the differential diagnosis of ACTH-dependent Cushing's syndrome. Furthermore, these data suggest that there may be abnormalities in vasopressin receptor function or number in ACTH-secreting tumors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8989255     DOI: 10.1210/jcem.82.1.3674

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  14 in total

1.  GHRP-6 is able to stimulate cortisol and ACTH release in patients with Cushing's disease: comparison with DDAVP.

Authors:  J H A Oliveira; J G H Vieira; J Abucham; A M J Lengyel
Journal:  J Endocrinol Invest       Date:  2003-03       Impact factor: 4.256

2.  Recurrence of Cushing's disease preceded by the reappearance of ACTH and cortisol responses to desmopressin test.

Authors:  Chiara Dall'Asta; Laura Barbetta; Luigi Bonavina; Paolo Beck-Peccoz; Bruno Ambrosi
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

Review 3.  Dynamic testing in Cushing's syndrome.

Authors:  Blerina Kola; Ashley B Grossman
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

4.  Selective inferior petrosal sinus sampling without venous outflow diversion in the detection of a pituitary adenoma in Cushing's syndrome.

Authors:  Lukas Andereggen; Gerhard Schroth; Jan Gralla; Rolf Seiler; Luigi Mariani; Jürgen Beck; Hans-Rudolf Widmer; Robert H Andres; Emanuel Christ; Christoph Ozdoba
Journal:  Neuroradiology       Date:  2011-08-02       Impact factor: 2.804

5.  ACTH and cortisol responses to ghrelin and desmopressin in patients with Cushing's disease and adrenal enlargement.

Authors:  D Miljic; M Joksimovic; M Doknic; M Ivovic; M Djurovic; S Pekic; M Tancic; I Soldatovic; M Stojanovic; Dj Nale; Dj Macut; S Damjanovic; V Popovic
Journal:  J Endocrinol Invest       Date:  2010-02-05       Impact factor: 4.256

6.  Second-line tests in the differential diagnosis of ACTH-dependent Cushing's syndrome.

Authors:  Mattia Barbot; Laura Trementino; Marialuisa Zilio; Filippo Ceccato; Nora Albiger; Andrea Daniele; Anna Chiara Frigo; Rodica Mardari; Giuseppe Rolma; Marco Boscaro; Giorgio Arnaldi; Carla Scaroni
Journal:  Pituitary       Date:  2016-10       Impact factor: 4.107

Review 7.  Peri-operative management of Cushing's disease.

Authors:  Dima AbdelMannan; Warren R Selman; Baha M Arafah
Journal:  Rev Endocr Metab Disord       Date:  2010-06       Impact factor: 6.514

Review 8.  Pituitary tumor diagnosis and treatment.

Authors:  Paul L Penar; David J Nathan; Muriel H Nathan; Afshin Salsali
Journal:  Curr Neurol Neurosci Rep       Date:  2002-05       Impact factor: 5.081

Review 9.  Arginine vasopressin (AVP): a review of its historical perspectives, current research and multifunctional role in the hypothalamo-hypophysial system.

Authors:  Fabio Rotondo; Henriett Butz; Luis V Syro; George M Yousef; Antonio Di Ieva; Lina M Restrepo; Andres Quintanar-Stephano; Istvan Berczi; Kalman Kovacs
Journal:  Pituitary       Date:  2016-08       Impact factor: 4.107

Review 10.  Pitfalls in Performing and Interpreting Inferior Petrosal Sinus Sampling: Personal Experience and Literature Review.

Authors:  Jordan E Perlman; Philip C Johnston; Ferdinand Hui; Guy Mulligan; Robert J Weil; Pablo F Recinos; Divya Yogi-Morren; Roberto Salvatori; Debraj Mukherjee; Gary Gallia; Laurence Kennedy; Amir H Hamrahian
Journal:  J Clin Endocrinol Metab       Date:  2021-04-23       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.